- Report
- April 2025
- 200 Pages
Global
From €4011EUR$4,490USD£3,482GBP
- Report
- June 2025
- 329 Pages
Global
From €4422EUR$4,950USD£3,838GBP
- Report
- September 2024
- 336 Pages
Global
From €4422EUR$4,950USD£3,838GBP
- Report
- May 2025
- 193 Pages
Global
From €3167EUR$3,545USD£2,749GBP
€3519EUR$3,939USD£3,054GBP
- Report
- May 2025
- 183 Pages
Global
From €3167EUR$3,545USD£2,749GBP
€3519EUR$3,939USD£3,054GBP
- Report
- May 2025
- 192 Pages
Global
From €3167EUR$3,545USD£2,749GBP
€3519EUR$3,939USD£3,054GBP
- Report
- May 2025
- 197 Pages
Global
From €3167EUR$3,545USD£2,749GBP
€3519EUR$3,939USD£3,054GBP
- Report
- June 2025
- 138 Pages
Global
From €2679EUR$2,999USD£2,325GBP
- Report
- May 2025
- 175 Pages
Global
From €4011EUR$4,490USD£3,482GBP
- Report
- April 2025
- 175 Pages
Global
From €4011EUR$4,490USD£3,482GBP
- Report
- March 2025
- 250 Pages
Global
From €4011EUR$4,490USD£3,482GBP
- Report
- July 2025
- 273 Pages
Global
From €5226EUR$5,850USD£4,536GBP
- Report
- July 2025
- 196 Pages
Global
From €5226EUR$5,850USD£4,536GBP
- Report
- April 2025
- 182 Pages
Global
From €3417EUR$3,825USD£2,966GBP
€4020EUR$4,500USD£3,489GBP
- Clinical Trials
- July 2025
- 280 Pages
Global
From €2680EUR$3,000USD£2,326GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2680EUR$3,000USD£2,326GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1117EUR$1,250USD£969GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1117EUR$1,250USD£969GBP
- Report
- May 2025
- 114 Pages
Global
From €4243EUR$4,750USD£3,683GBP
- Report
- June 2025
- 150 Pages
Global
From €2411EUR$2,699USD£2,093GBP

Ranibizumab is a monoclonal antibody used to treat optical disorders such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). It is administered as an intravitreal injection, and works by inhibiting the activity of vascular endothelial growth factor (VEGF), which is responsible for the growth of abnormal blood vessels in the eye. Ranibizumab is the first anti-VEGF drug approved by the US Food and Drug Administration (FDA) for the treatment of wet AMD, and is now widely used in the treatment of other optical disorders.
Ranibizumab is available in both branded and generic forms, and is marketed by a number of pharmaceutical companies, including Novartis, Regeneron, Genentech, and Allergan. Show Less Read more